Today's top medical abstracts
Rheumatology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Rheumatology
For Practicing
Rheumatologists
Conferences
Jobs
Newsletters
My Library
Topics in
Rheumatology
        Amyloidosis
        Autoimmune/Heritable
        Basic Science/Genetics
        Bone Metabolism
        Chr Fatigue/Fibromyalgia
        Clinical Pharmacology
        Connective Tissue Dz
        Diagnostics/Radiology
        Economics of Medicine
        Gout and Hyperuricemia
        Infectious Arthritis
        Osteoarthritis
        Other Arthritis
        Pediatric Rheumatology
        Popular Press
        Rheumatoid Arthritis
        Spondylarthropathies
        Systemic Lupus (SLE)
        Vasculitic Syndromes
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Rheumatologists
Today's Rheumatology News: VGX-1027 To Undergo Additional Testing For RA
D Scott Cunningham MD, PhD, MDLinx Rheumatology
Today's Rheumatology News: FDA Approves Actemra
D Scott Cunningham MD, PhD, MDLinx Rheumatology
From the Editors: New Clinical-Only Option for MDLinx!
Stephen Smith, MDLinx
  See all
knee joints;DMARDs treatment Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Enhanced MRI in early undifferentiated oligoarthritis of the knee joints: Improvements already visible after 2 months of DMARDs treatment
Clinical Rheumatology, 06/25/08
Print     Email This Article     Save in My Library   Free Abstract
Emad Y et al. – This study reports that after 2 months treatment with methotrexate (MTX) and hydroxychloroquine (HCQ), the MRI improved considerably especially regarding synovial thickening in patients with early undifferentiated oligoarthritis of knee joints.

Methods
  • Study to describe (i) the findings with MRI in pts with early undifferentiated OA of the knee joint(s) and (ii) the early effect after 2 mos of treatment with only MTX and HCQ
  • 15 consecutive pts with undifferentiated OA of the knee joint(s) were recruited
  • The mean age: 31.7 yrs; mean disease duration: 15.3 mos
  • Synovial fluid analysis, RF, anti-CCP2 antibodies, ANA, CRP, ESR, and routine laboratory investigations were performed in all pts
  • Enhanced MRI was done at initial evaluation and after 2 mos treatment

Results
  • 4/15 pts had positive RF and 6 had positive anti-CCP2
  • After treatment with DMARDs, a regression was seen regarding effusion and synovitis in all pts
  • In 1/3 pts, the bone edema had regressed
  • Synovial thickening as measured by enhanced MRI decreased significantly and correlated with the improved ESR and CRP

Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.